<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04868838</url>
  </required_header>
  <id_info>
    <org_study_id>20-010520</org_study_id>
    <nct_id>NCT04868838</nct_id>
  </id_info>
  <brief_title>Daratumumab to Treat Active Lupus Nephritis</brief_title>
  <official_title>A Phase 2 Open-label Trial Evaluating the Efficacy and Safety of Daratumumab in Treatment of Patients With Active Lupus Nephritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to study the safety and efficacy of daratumumab in inducing&#xD;
      complete or partial remission in patients with active lupus nephritis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 20, 2021</start_date>
  <completion_date type="Anticipated">September 4, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 15, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of daratumumab in inducing complete(CR) or partial(PR) renal remission in patients with active class III or IV Lupus Nephritis</measure>
    <time_frame>12 months after first infusion of Daratumumab</time_frame>
    <description>Complete Renal Response:- &lt; 500 mg proteinuria/24 hours, Inactive urinary sediment (&lt;10 RBC/HPF and absence of RBC casts), No greater than a 15% reduction in eGFR from enrollment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy of daratumumab in inducing complete(CR) or partial(PR)</measure>
    <time_frame>12 months after first infusion of Daratumumab</time_frame>
    <description>Partial Renal Response: &gt; 50% reduction in 24-hour proteinuria and proteinuria &lt; 1g/24hr if baseline 24hr proteinuria, - ≤3 g/24hr and proteinuria ≤ 3 g/24hr if starting proteinuria &gt; 3 g/24hrs. , Improved urinary sediment (&gt;=50% reduction in RBC/HPF and absence of RBC casts), No greater than a 20% reduction in baseline eGFR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of daratumumab in patients with active class III/IV LN.</measure>
    <time_frame>24 months after first infusion of Daratumumab</time_frame>
    <description>Incidence of major infections defined in the development of pneumonia, grade 3 urinary tract infection/pyelonephritis, sepsis, meningitis or anemia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement from proteinuria</measure>
    <time_frame>Baseline, 6, 12, 18 and 24 months after first infusion of Daratumumab</time_frame>
    <description>Change in proteinuria in milligrams (mg) per 24h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hematuria.</measure>
    <time_frame>Baseline,6, 12, 18 and 24 months after first infusion of Daratumumab</time_frame>
    <description>Improvement in hematuria from baseline as measured by the urinalysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in eGFR</measure>
    <time_frame>Baseline, 6, 12, 18 and 24 months after first infusion of Daratumumab</time_frame>
    <description>Improvement in eGFR measured using the chronic kidney disease epidemiology collaboration (CKD-EPI) Equation: eGFR (CKD-EPI) = 141 x min(Scr/k, 1)alpha x max(Scr/k,1)-1.209 x 0.993age x 1.018 (if patient is female) x 1.159 (if patient is black)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ds-DNA</measure>
    <time_frame>Baseline, 6, 12, 18 and 24 months after first infusion of Daratumumab</time_frame>
    <description>Improvement in ds-DNA in International units per milliliter (IU/mL)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Lupus Nephritis</condition>
  <arm_group>
    <arm_group_label>Daratumumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects diagnosed with lupus nephritis will receive Daratumumab once weekly for 8 weeks and then once every 2 weeks for 8 additional does (+/- 4 days). Subjects will be followed for a total of 24 months (18 months after the last daratumumab administration).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daratumumab</intervention_name>
    <description>1800 mg administered by subcutaneous injection by manual push over approximately 3-5 minutes in the abdominal subcutaneous tissues in the left/right locations, alternating between individual doses.</description>
    <arm_group_label>Daratumumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years of age.&#xD;
&#xD;
          -  Diagnosis of SLE according to current American College of Rheumatology (ACR) criteria.&#xD;
&#xD;
          -  Renal biopsy confirming the diagnosis of active class III/IV (± class V) LN (based on&#xD;
             International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003) within 12&#xD;
             months of enrollment.&#xD;
&#xD;
          -  Proteinuria ≥ 500 mg over 24 hours.&#xD;
&#xD;
          -  eGFR ≥ 30 ml/min/SA.&#xD;
&#xD;
          -  Subjects should be able to give informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy.&#xD;
&#xD;
          -  Hepatitis B or C, HIV&#xD;
&#xD;
          -  Anemia with Hgb &lt; 8.0 g/dL.&#xD;
&#xD;
          -  Thrombocytopenia with platelet count &lt; 100'000.&#xD;
&#xD;
          -  Any other disease, metabolic dysfunction, physical examination finding, or clinical&#xD;
             laboratory finding giving reasonable suspicion of a disease or condition that&#xD;
             contraindicates the use of an investigational drug or that may affect the&#xD;
             interpretation of the results or render the patient at high risk from treatment&#xD;
             complication.&#xD;
&#xD;
          -  Unable to provide consent.&#xD;
&#xD;
          -  Patients receiving &gt; 10 mg of oral prednisone or glucocorticoid equivalent if on&#xD;
             corticosteroids for &gt; 2 weeks (patients would be allowed to be on &gt; 10 mg of&#xD;
             prednisone or its oral equivalent as long as the duration is ≤ 2 weeks).&#xD;
&#xD;
          -  Patients who had received immunosuppressive therapy including cyclosporine, tacrolimus&#xD;
             or azathioprine in the last 3 months.&#xD;
&#xD;
          -  Patients who have received cyclophosphamide in the last 6 months.&#xD;
&#xD;
          -  Patients who received rituximab previously with CD20 count of zero at the time of&#xD;
             enrollment.&#xD;
&#xD;
          -  Patient are allowed to be on MMF at time of enrollment but no higher than total of&#xD;
             1500mg/day.&#xD;
&#xD;
          -  For women who are not postmenopausal (≥ 12 months of non-therapy-induced amenorrhea)&#xD;
             or surgically sterile (absence of ovaries and/or uterus): agreement to remain&#xD;
             abstinent or use two adequate methods of contraception, including at least one method&#xD;
             with a failure rate of less than (&lt;) 1 percent (%) per year, during the treatment&#xD;
             period and for at least 12 months after the last dose of study drug.&#xD;
&#xD;
          -  For men: agreement to remain abstinent or use a condom plus an additional&#xD;
             contraceptive method that together result in a failure rate of &lt; 1% per year during&#xD;
             the treatment period and for at least 12 months after the last dose of study drug and&#xD;
             agreement to refrain from donating sperm during this same period.&#xD;
&#xD;
          -  Patients with diagnosis of glaucoma.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fernando C Fervenza</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Leah Majerus</last_name>
    <phone>507-266-1047</phone>
    <email>majerus.leah@mayo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Brittany Price</last_name>
    <phone>507-266-0956</phone>
    <email>price.brittany@mayo.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leah M Majerus</last_name>
      <phone>507-266-1047</phone>
      <email>majerus.leah@mayo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Gabriell Hills</last_name>
      <phone>507-266-4616</phone>
      <email>Gabrielle@mayo.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Fernando Fervenza, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zand Ladan, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 20, 2021</study_first_submitted>
  <study_first_submitted_qc>April 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2021</study_first_posted>
  <last_update_submitted>May 19, 2021</last_update_submitted>
  <last_update_submitted_qc>May 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Fernando Fervenza</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nephritis</mesh_term>
    <mesh_term>Lupus Nephritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Daratumumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Plan pending</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

